logo

Cerevel Therapeutics Holdings Inc. (CERE)



Trade CERE now with
  Date
  Headline
8/12/2022 6:13:02 AM Cerevel Therapeutics Prices Public Offering Of 7.25 Mln Shares At $35/Shr
2/15/2022 6:55:47 AM Cerevel Therapeutics Announces Positive Topline Results For Darigabat In Phase 1 Clinical Trial In Acute Anxiety
11/10/2021 6:45:57 AM Cerevel Therapeutics Q3 Loss Per Share $0.43 Vs Loss $0.62 Last Year
4/13/2021 6:42:15 AM Cerevel Therapeutics Announces $125 Mln Non-dilutive Financing Transaction With NovaQuest, Bain Capital For Tavapadon
3/24/2021 6:46:28 AM Cerevel Therapeutics Q4 Net Loss Attributable To Common Stockholders $29.3 Mln Or $0.27 Per Share
7/12/2013 12:45:27 PM Barclays Capital Is Increasing CERES, INC. (CERE) FY14 Estimate To -0.79 From -1.08
7/12/2013 12:45:06 PM Barclays Capital Is Cutting CERES, INC. (CERE) FY13 Estimate To -1.27 From -1.25
4/17/2013 12:31:11 PM Barclays Capital Is Raising CERES, INC. (CERE) FY14 Estimate To -1.08 From -1.15
1/11/2013 12:40:42 PM Barclays Capital Is Lowering CERES, INC. (CERE) FY14 Estimate To -1.15 From -1.01
1/11/2013 12:40:24 PM Barclays Capital Is Lowering CERES, INC. (CERE) FY13 Estimate To -1.25 From -1.23
11/21/2012 12:42:31 PM Barclays Capital Is Cutting CERES, INC. (CERE) FY13 Estimate To -1.23 From -1.18
7/13/2012 2:13:24 PM Barclays Capital Is Lowering CERES, INC. (CERE) FY12 Estimate To -1.20 From -1.10
6/8/2012 12:06:31 PM Barclays Capital Starts CERES, INC. (CERE) At Overweight With $18 Price Target